These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 11753652)

  • 1. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
    Brasher BB; Roumiantsev S; Van Etten RA
    Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
    Van Etten RA; Debnath J; Zhou H; Casasnovas JM
    Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An intramolecular SH3-domain interaction regulates c-Abl activity.
    Barilá D; Superti-Furga G
    Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
    Pisabarro MT; Serrano L; Wilmanns M
    J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the specificity of Src homology 3 domain--ligand interactions with alkaline phosphatase fusion proteins.
    Yamabhai M; Kay BK
    Anal Biochem; 1997 Apr; 247(1):143-51. PubMed ID: 9126384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
    Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the proline-rich region of mouse MAPKAP kinase 2: influence on catalytic properties and binding to the c-abl SH3 domain in vitro.
    Plath K; Engel K; Schwedersky G; Gaestel M
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1188-94. PubMed ID: 8093038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
    Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
    Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.
    Gonfloni S; Weijland A; Kretzschmar J; Superti-Furga G
    Nat Struct Biol; 2000 Apr; 7(4):281-6. PubMed ID: 10742171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domain interactions in protein tyrosine kinase Csk.
    Sondhi D; Cole PA
    Biochemistry; 1999 Aug; 38(34):11147-55. PubMed ID: 10460171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
    Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
    Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C-terminal SH3 domain of p67phox binds its natural ligand in a reverse orientation.
    Finan P; Koga H; Zvelebil MJ; Waterfield MD; Kellie S
    J Mol Biol; 1996 Aug; 261(2):173-80. PubMed ID: 8757285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
    Oda T; Kujovich J; Reis M; Newman B; Druker BJ
    Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement.
    Moarefi I; LaFevre-Bernt M; Sicheri F; Huse M; Lee CH; Kuriyan J; Miller WT
    Nature; 1997 Feb; 385(6617):650-3. PubMed ID: 9024665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
    Mysliwiec T; Perego R; Kruh GD
    Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain.
    Pisabarro MT; Serrano L
    Biochemistry; 1996 Aug; 35(33):10634-40. PubMed ID: 8718852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
    Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
    Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
    Miyazaki K; Senga T; Matsuda S; Tanaka M; Machida K; Takenouchi Y; Nimura Y; Hamaguchi M
    Biochem Biophys Res Commun; 1999 Oct; 263(3):759-64. PubMed ID: 10512753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reexamination of the recognition preference of the specificity pocket of the Abl SH3 domain.
    Santamaria F; Wu Z; Boulègue C; Pál G; Lu W
    J Mol Recognit; 2003; 16(3):131-8. PubMed ID: 12833568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.